Stephen Squinto, chief investment officer and managing partner for JP Morgan Life Sciences Private Capital
Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund
Over a year and a half since its inception, JP Morgan’s life sciences investment arm has closed its first biotech venture capital fund with over …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
